🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions

RecruitingNAAges 18 Years - anyMaleCopenhagen University Hospital, Rigshospitalet
NCT07343349 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and globally. The aim is to reduce later cancer spreading, need of hormone treatments and prostate cancer death. DAPROCA 10 tests two possible improvements: If a higher dose (boost) to intra-prostatic tumor lesions improves cure rates. If the radiotherapy can be given with 12 treatment fractions instead of 20 without increased side-effects. In this randomised trial half the participants get a boost and the other half don't. Half the patients get 12 treatments, the other half 20. To answer these questions we must include1016 participants. The trial is feasible because the technological advances in imaging and radiotherapy enables us to define the tumors in the prostate

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with biopsy verified PCa with no distant metastases with either * Intermediate- or high-risk PCa, defined as at least one of the following risk criteria: * Clinical stage cT2c-T3b (UICC TNM 8th edition) * Imaging stage, T3a or T3b * ≥ Gleason score 4+3, (ISUP Grade groups 3,4 or 5) * Regional lymph node metastases N1 * Age \> 18 * WHO score 0-1 * Intraprostatic lesion visible on MRI * Suitable for focal boost * Ability to give written informed consent and willingness to return for follow-up Exclusion Criteria: * WHO performance status ≥ 2 * If, for any patient related reason, an MRI cannot be performed * T4 * International prostate symptom score (IPSS) ≧ 20 * If fiducial markers cannot be inserted * TURP within 3 months from start of treatment * Previous pelvic irradiation * If the patient is judged by the physician to be unable to adhere to trial activities * History of chronic inflammatory bowel disease (CIBD)
💊

What it tests

  • Addition of focal boost and hypofractionation
📍

Where

3 sites
Aurhus University Hospital
Aarhus, Denmark
Rigshospitalet
Copenhagen, Denmark
Sygehus Lillebaelt
Vejle, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy